1) Strong Financial Performance and Guidance Update
- Total revenues for Q2 2026 were $3.8 billion, reflecting 3.5% operational growth YoY.
- Adjusted EBITDA reached $1.2 billion, with adjusted EPS at $0.69 per share.
- The company raised its financial guidance for 2026, anticipating operational growth of approximately 2% for total revenues, 5% for adjusted EBITDA, and 7% for adjusted EPS.
- The updated outlook accounts for expected manufacturing disruptions at the Nashik facility, which may impact revenues by $100 million to $150 million in the second half of 2026.

2) Strategic Initiatives and Pipeline Progress
- Viatris is focusing on high-growth opportunities, including the recent U.S. regulatory approval for Gwyn Lo, a transdermal contraceptive patch, expected to launch later this year.
- The company is also preparing for the launch of fast-acting meloxicam, with positive FDA engagement and anticipated approval by year-end.
- Ongoing Phase III programs for selatogrel and cenerimod are on track, with significant readouts expected in 2027, which could lead to long-term blockbuster growth opportunities.

3) Market Performance and Regional Highlights
- Greater China saw a remarkable 16% YoY growth, driven by strong demand for cardiovascular products and strategic investments in marketing.
- North America reported a 1% growth, supported by complex generics and transdermal products, while Europe and emerging markets faced challenges with slight declines.
- The company remains cautious about potential impacts from new procurement policies in China and competitive pressures in developed markets.

4) Operational Challenges and Remediation Plans
- The Nashik facility experienced intermittent manufacturing disruptions due to a fire and FDA inspection observations, which are expected to affect lower-margin products.
- Viatris is implementing a comprehensive remediation plan and is in communication with the FDA to address the inspection findings.
- The company is confident that these operational challenges are manageable and will not have long-term effects on the business.

5) Investor Outlook and Strategic Focus
- Viatris is committed to disciplined capital allocation, returning approximately $550 million to shareholders through dividends and share repurchases.
- The company is exploring M&A opportunities to enhance its portfolio while maintaining a strong balance sheet with a gross leverage ratio of approximately 2.9x.
- The management expressed optimism about the long-term growth potential driven by their diversified portfolio and strategic investments, although specific future guidance remains cautious due to market uncertainties.

Bottom line: Viatris is demonstrating strong operational momentum and strategic execution, with a robust pipeline and solid financial performance. Despite facing some operational challenges, the company is well-positioned for sustainable long-term growth, making it an attractive prospect for shareholders.